This is really confusing as to why the final phase II results showed overall survival rate of 15.7 months and PFS of 8.6 months which the company said exceeds the standard of care? The AGILE study is saying otherwise?
- Forums
- ASX - By Stock
- KZA
- Ann: GBM Agile Update
Ann: GBM Agile Update, page-57
-
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)